Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors

• Autors principals: Alice Ramondetta (Autor), Simone Ribero (Autor), Luca Conti (Autor), Paolo Fava (Autor), Elena Marra (Autor), Paolo Broganelli (Autor), Virginia Caliendo (Autor), Franco Picciotto (Autor), Michele Guida (Autor), Maria Teresa Fierro (Autor), Pietro Quaglino (Autor)
• Format: Llibre
• Publicat: Medical Journals Sweden, 2020-01-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Current therapies for metastatic melanoma (anti-PD1 and BRAF/MEK inhibitors) can cause drug-induced vitiligo. The aim of this study is to dermatologically define and histologically characterize this new type of vitiligo, and assess the clinical course of the disease. Fourteen patients with metastati...